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Aims: Most reports estimating national incidence rates of coronary (CAD) and peripheral arterial 
disease (PAD) have focused on stable outpatients or acute or elective hospital admissions, but not on 
the overall burden of disease. In this study, we report the changing trends in the population level 
incidence of CAD and PAD respectively from 2006 to 2015, statin utilisation for secondary prevention 
and survival outcomes using multiple nationally representative data sources from the UK (primary 
care encounters, hospital admissions and procedure level data).  
Methods and results: A nationally representative study of linked primary and secondary care 
electronic health records of 4.6 million individuals from the UK. We calculated crude and standardised 
annual incidence rates separately for CAD and PAD. Statin use for secondary prevention, trends in 
annual major vascular event rates, and mortality between 2006 and 2015, were estimated for CAD 
and PAD respectively. We identified 160,376 and 70,753 patients with incident CAD and PAD 
respectively. The age and sex-standardised incidence of CAD was similar in 2006 (443 per 100,000 
person years [pyrs]) and 2015 (436 per 100,000 pyrs; adjusted incidence rate ratio [IRR] 0.98, 95%CI 
0.96-1.00). By contrast, there was a 15% decline in the standardised incidence of PAD (236 per 100,000 
pyrs in 2006 to 202 per 100,000 pyrs in 2015; adjusted IRR 0.85, 95%CI 0.82-0.88). The proportion of 
incident CAD and PAD patients prescribed long-term statins, was only 66% and 55% respectively and 
was less common amongst women, patients aged >70 years, with heart failure, chronic lung disease 
or depression. CV mortality declined by 43% for incident CAD (adjusted IRR: 0.57, 95%CI: 0.50-0.64) 
between 2006 and 2015 but did not decline for incident PAD (adjusted IRR: 0.84, 95%CI: 0.70-1.00). 
Conclusion and Relevance: In the UK, the standardised incidence of CAD appears stable but mortality 
rates are falling whereas the standardised incidence of PAD is falling but mortality rates are not. 
  
Introduction  
For the past four decades, high-income countries have experienced a tremendous decline in the 
standardised incidence rates of atherosclerotic cardiovascular disease (ASCVD) and cardiovascular 
(CV) mortality.1–6  Nevertheless, ASCVD remains one of the leading causes of death and disability-
adjusted life-years.7–9 The clinical spectrum of ASCVD is wide and can be broadly categorised into those 
involving the coronary arteries (CAD), other vascular beds (e.g., peripheral arterial disease-PAD) or 
both.10,11 Estimating the population level incidence of ASCVD stratified by the involvement of vascular 
beds may help inform health policy, as resource utilisation and economic burden related to 
management may be influenced by the type of vascular beds involved.12,13 
Most previous studies estimating the incidence of CAD have included either chronic ischemic heart 
disease from general practice (GP) consultations or acute myocardial infarction (AMI) from hospital 
admissions. 8, 12–14 Previous studies have shown that failure to use linked primary and secondary care 
data can lead to a substantial (25-50%) underestimate of the burden of CAD.17 Therefore, analyses of 
clinical encounters across the entire spectrum of health care services (both inpatient and outpatient) 
are required to capture the full burden of CAD.  
Peripheral arterial disease (PAD) is reported to affect about 13% of people aged greater than 50 years 
in Western Europe and North America.10,18,19 In spite of its high prevalence and poor prognosis, PAD 
attracts less attention in terms of research, early detection, and treatment. 20,21 There is a paucity of 
PAD data in terms of geographic and secular trends in the incidence, patient characteristics, treatment 
patterns, and survival. 
Accordingly, we investigated the changing incidence of CAD and PAD respectively from 2006 to 2015, 
using multiple data sources (GP consultations, hospital admissions and procedure level data) that are 
representative of the UK population. We also investigated the regional variations in the incidence, 
trends in cardiovascular (CV) risk factors, statin use for secondary prevention, trends in annual major 
vascular event rates and mortality among patients with incident CAD and PAD respectively, from 2006 
to 2015. 
Methods  
Data source  
Primary care records from general practitioners (GPs) caring for about 9% of the UK population (about 
6 million people) were obtained from the Clinical Practice Research Datalink (CPRD) covering the 
period between January 1st, 1986 to December 31st, 2016.22 Data from CPRD were linked to the 
hospital episode statistics (HES), which contains in-patient diagnostic and procedural records, and to 
the Office of National Statistics (ONS) for information on the date and cause of death.  
Study population  
People aged at least 18 years old with CAD or PAD were identified from CPRD using READ codes,  from 
HES using International Classification of Diseases, tenth revision (ICD-10) codes and from Office of 
Population Censuses and Surveys Classification of Surgical Operations and Procedures  (OPCS) revision 
4.6 for codes for coronary and peripheral revascularisations (Supplementary Appendix; Tables S4-S5). 
READ codes used in CPRD are the standard clinical terminology system used in General Practice in the 
UK.  READ codes gives detailed clinical coding of multiple patient features such as occupation; social 
circumstances; ethnicity and religion; clinical signs, symptoms and observations; laboratory tests and 
results, medications and diagnoses.23 Patients with a prior diagnosis (before 1st January, 2006) of CAD 
or PAD (prevalent disease) were excluded for incidence calculation of CAD or PAD respectively. The 
incident diagnosis was defined as the first record of diagnosis in the primary care or hospital admission 
records. Incident cases (for both CAD and PAD) formed the base cohort for analyses of statin 
prescribing (Statin cohort) and HES linkage (Complications cohort) (Supplementary Figures S1 and S2)  
The investigation of statin use and its predictors was restricted to patients with incident CAD and PAD 
aged greater than 40 years who had complete follow-up data for at least one year from the date of 
diagnosis. Those transferring out of a CPRD participating GP practice or whose last collection date was 
within a year of diagnosis were excluded (Supplementary Figure S1 and S2). Patients who could be 
linked to HES and ONS (~ 60% of patients in CPRD) were used to evaluate trends in the annual rates 
of major vascular events and mortality between 2006 and 2015. 
Patient characteristics  
Common co-morbidities were identified using CPRD READ codes. Socioeconomic status was reported 
using Index of Multiple Deprivation (IMD) 2015 quintiles, with quintile 1 being the least and quintile 5 
the most deprived. Information on geographic region, ethnicity, other relevant clinical variables such 
as body mass index and baseline medications (prior to incident diagnosis) including antiplatelet 
therapy, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blockers 
(ACEI/ARB), beta-blockers, calcium channel blockers and other vasodilators were also analysed. 
Outcomes  
The individual trends in the incidence of CAD and PAD between 2006 and 2015 were the primary 
outcomes of interest. The overall proportion of patients on a stable treatment regimen of statins, 
stratified by the type of vascular disease (CAD and PAD) and co-morbidities are described. A stable 
treatment regimen of statins was defined as prescriptions for more than 75% (273.75/365.25 days) of 
the first year after incident diagnosis. Finally, we present trends (from 2006 to 2015) in the annual age 
and sex adjusted event rates of complications including, myocardial infarction, stroke, hospitalisation 
for bleeding, CV hospitalisation (planned and unplanned), premature CV mortality (defined as death 
<75 years), CV mortality and all-cause mortality among patients with incident CAD and incident PAD.   
Statistical analyses 
Baseline characteristics were expressed using mean ± standard deviation for continuous variables and 
percentages for categorical variables. Baseline characteristics were stratified by sex and three time 
periods of diagnosis (2006-07, 2010-11 & 2014-2015). We calculated sex and age specific (5 year 
intervals) incidence rates per 100,000 person years for each year. For the denominator the total 
person years in each year was calculated in 5 year age intervals. Standardised incidence rates were 
computed individually for CAD and PAD on the basis of 2013 European standard population 
distribution of age and sex.24 We employed Poisson regression models to estimate adjusted incidence 
rate ratios (IRR) and 95% confidence intervals (CI) for quantifying the change in the incidence rates 
between 2006 and 2015. 25 
The proportion of incident CAD and incident PAD patients on statins, stratified by baseline co-
morbidities were analysed. Logistic regression model was used to investigate the predictors of statin 
use (or non-use) after an incident diagnosis, separately for patients with incident CAD and patients 
with incident PAD. We adjusted the model for age, sex, year of diagnosis, and relevant co-morbidities 
including, diabetes mellitus (DM), hypertension (HTN), chronic kidney disease (CKD), chronic 
obstructive pulmonary disease (COPD), depression, dementia, history of malignancy, chronic liver 
disease (CLD), prior history of PAD or CAD, and prior history of ischemic stroke. 
The event rates of complications were defined as the annual rate of occurrence (per 100 person years) 
of the complications during the first year of follow up. Total follow-up was calculated from the time 
of incident CAD or PAD diagnosis in CPRD or HES and the date of the outcome (i.e. first event for each 
outcome of interest), death (when it is not the outcome), date of disenrollment in the practice or of 
the practice in CPRD, or the end of follow up (one year from the date of incident diagnosis). Rates 
were age and sex standardised to 2013 European Standard Population. For all the complications, we 
computed adjusted IRR and 95% CI to estimate changes in the event rates over time (2006 to 2015), 
separately for incident CAD and incident PAD patients. We performed sensitivity analyses for event 
rates and mortality in incident PAD patients by excluding those with history of concomitant CAD 
(Please see Supplementary Appendix for details).  
Ethics approval 
The study was approved by the Independent Scientific Advisory Committee of the Medicine and 
Healthcare Products Regulatory Agency (MHRA) for database research (protocol number: 18_057R). 
The data are anonymous, and the requirement for informed consent was therefore waived. 
Role of funding source 
The present work was funded by a research grant from Bayer. VS and JKQ had full access to all the 
data and all authors made the final decision to publish. We had two Bayer representatives that were 
engaged in the project: KB and JBB. Both representatives participated to the funding of the study. KB 
and JBB were not involved in the data analyses and the results interpretations. No Bayer drug was 
involved in the study limiting risk of potential conflict of interest. 
Results  
From 15.4 million patient records, 4,618,735 people who were alive on Jan 1, 2006 were identified of 
whom 184,814 had prevalent CAD and 52,667 had prevalent PAD (Supplementary Figure S1 and S2). 
Between 2006 and 2015, 160,376 incident cases of CAD (base-cohort for CAD) and 70,753 incident 
cases of PAD (base-cohort for PAD) were identified. Using multiple data sources, compared to using 
primary care encounters only, we identified an additional 38,207 cases of incident CAD (25% increase) 
and 4,500 incident cases of PAD (7% increase) (Supplementary Figure S3).  
Incidence of CAD and PAD  
Across the UK, there was no change in the age- and sex-standased incidence of CAD between 2006 
and 2015 [443 per 100,000 person years in 2006 and 436 per 100,000 person years in 2015; adjusted 
IRR 0.98, 95% CI 0.96 - 1.00] (Figure 1). Similarly, there was no change in the crude incidence for CAD 
from 439 per 100,000 person years in 2006 to 450 per 100,000 person years in 2015 (IRR 1.02, 95% CI 
1.00 - 1.05) (Figure 2). The age-standardised incidence of CAD was higher amongst men (650 per 
100,000 person years) than women (370 per 100,000 person years) (Supplementary Figure S3 and S4). 
The trends in standardised incidence of CAD among men and women remained relatively stable from 
2006 to 2015 (adjusted IRR for men 1.00, 95% CI 0.96 – 1.03; adjusted IRR for women 0.97, 95% CI 
0.93 – 1.00) (Supplementary Figures S4 and S5). In keeping with the overall trend for CAD (which 
included chronic ischemic heart disease and AMI), the age- and sex-adjusted incidence rates for AMI 
were similar in 2006 and 2015 (adjusted IRR 0.99, 95% CI 0.95 – 1.03). We observed a transient 
increase in the age- and sex-standardised incidence of CAD peaking in 2008, similar to an earlier report 
on AMI in the UK (please see supplementary appendix for details).14 
There was a 15% decline in the age- and sex-standardised incidence of PAD from 236 per 100,000 
person years in 2006 to 202 per 100,000 person years in 2015 (adjusted IRR 0.85, 95% CI 0.82 - 0.88) 
(Figure 1). In line with the standardised rates, there was 10% decline in the crude incidence of PAD – 
falling from 234 per 100,000 person years in 2006 to 211 per 100,000 person years in 2015 (IRR 0.90, 
95% CI 0.87 - 0.93) (Figure 2). The decrease in the standardised incidence of PAD over time was 
consistent across most of the age groups. Age-standardised PAD incidence was higher in men (300 per 
100,000 person years) than women (156 per 100,000 person years). Reductions in the age-
standardised incidence of PAD in women from 2006 to 2015 (adjusted IRR for women 0.86, 95% CI 
0.81 – 0.91) exceeded those for men (adjusted IRR for men 0.93, 95% CI 0.89 – 0.97) (Supplementary 
Figures S4 and S5). 
Regional variations in the standardised incidence of CAD in England which were apparent in 2006, 
particularly the difference between the north and south, were lower in 2015 (Supplementary Figure 
S6). There was a substantial decline in the age and sex standardised incidence of PAD in the Northwest 
and North-eastern regions of England between 2006 and 2015 (>30% reduction in the standardised 
incidence of PAD) (Supplementary Figure S7). 
Patient characteristics stratified by sex and time period  
The mean age at diagnosis for CAD and PAD was similar and did not change between 2006 and 2015 
(Tables 1 and 2). Patients diagnosed in more recent years were more likely to be obese, have DM, 
CKD, dyslipidaemia and a history of cancer. Women were slightly older and had more co-morbidities 
than men. The use of statins and ACE inhibitors (for primary prevention) prior to an incident diagnosis 
increased substantially from 2006 to 2015 in both CAD and PAD (Table 1 and Table 2). 
  
Predictors of statin non-use for secondary prevention 
After applying the eligibility criteria for statin analyses, we included 121,011 incident cases of CAD and 
49,426 incident cases of PAD (Statin cohort) (Supplementary Figures S1 and S2, Supplementary Table 
S3). The proportion of incident cases of CAD and PAD who qualified as receiving a stable statin 
treatment regimen were 66% and 55% respectively. Notably, over 40% of women and 50% of elderly 
(age > 70 years) with established ASCVD (CAD and PAD), were not on a stable statin regimen (Table 3 
and Supplementary Table S2). In a multivariable logistic regression model, for patients with CAD, 
failure was associated with female sex (odds ratio [OR] 0.67, 95% CI 0.65 - 0.69), heart failure (OR 0.73, 
95% CI 0.69 – 0.78), age >70 years (OR 0.87, 95% CI 0.84 - 0.90), COPD (OR 0.82, 95% CI 0.78 – 0.86) 
and depression (OR 0.86, 95% CI 0.81 – 0.90) and was similar for PAD (Figure 3). Statin uptake did not 
increase significantly between 2006 and 2015 (Supplementary appendix Figure S7). 
Trends in the annual event rates of major vascular events and mortality from 2006 to 2015 
The overall annual age- and sex-standardised rates for MI were higher for CAD than for PAD but the 
reverse was true for ischemic stroke (Table 4). The age- and sex-standardised annual CV mortality was 
similar for CAD and PAD. However all-cause mortality was higher for PAD (9.2 per 100 person years, 
95% CI 9.0-9.5) compared to incident CAD (8.2 per 100 person years, 95% CI 8.1-8.4). Age-adjusted 
rates of MI and bleeding requiring hospitalisation were higher in men than in women for both CAD 
and PAD, whereas the rate of ischemic stroke for those with incident CAD group was higher in women 
(Table 4). Morbidity and mortality were similar for patients with PAD whether or not they had CAD 
(Supplementary Figure S10 and Supplementary Table S4). 
Comparing 2006 vs 2015, the annual age- and sex-adjusted rate of MI fell by 48% in those with incident 
CAD (adjusted IRR 0.52, 95% CI 0.43 - 0.63) and 56% in those with incident PAD (adjusted IRR 0.44, 
95% CI 0.32 – 0.61) (Figure 4). The greatest reduction in the annual event rates of stroke were 
observed in incident PAD patients [PAD: adjusted IRR 0.63 (0.45 - 0.89); CAD adjusted IRR 0.84 (0.66 - 
1.07)]. A marked decline in CV mortality (43%) was observed amongst cases of incident CAD from 2006 
to 2015 (adjusted IRR 0.57, 95% CI 0.50 – 0.64) which was less obvious amongst cases of incident PAD 
(adjusted IRR 0.86, 95% CI 0.70 – 1.00), with or without concomitant CAD (Figure 4, Supplementary 
Figure S10-S13). The rate of all-cause mortality fell amongst cases of incident CAD but rose amongst 
cases of PAD even after adjusting for age and sex. 
Discussion  
This study of a large nationally representative population in the UK over one decade provides vital 
insights into the trends in incidence, risk factors, statin use, major vascular complications and mortality 
of two important clinical spectrums of ASCVD – CAD and PAD.  
In contrast to previous studies that have reported a decline until 2010, the incidence of CAD in models 
standardised for age and sex, in our study, has remained relatively stable between 2006 and 2015.8,14 
The absence of decline in our study versus the findings of previous studies could have been caused by 
myriad reasons. To begin with, unlike previous studies, we included the entire spectrum of patients 
with CAD from all possible clinical encounters within the UK health system including chronic ischemic 
heart disease from GP encounters (READ codes), hospitalisations for AMI (HES codes) and from 
procedural records for coronary revascularisations (OPCS 4.6 codes). By this process, we identified an 
additional 38,207 incident CAD patients, a 25% increase (Figure 1), utilizing multiple nationally 
representative data sources in comparison to conventional case ascertainment using one data source 
only. Secondly, whilst improvements in primary prevention measures were expected to decrease the 
incidence of CAD, offsetting trends such as an increase in the prevalence of obesity, dyslipidaemia, 
diabetes and CKD may have attenuated the decline. Thirdly, previous studies on the incidence of AMI 
included patients with prior history of chronic ischemic heart disease.14,16,26 As result of this, some of 
those patients could have been on CV prevention medications, which in turn may have contributed to 
the decline in the incidence rates of AMI. Finally, there could have been an increase in the detection 
of non-ST elevation MI (NSTEMI), attributable to the introduction of high sensitivity troponin (hsTnT) 
as a diagnostic marker. The European Society Cardiology Study Group on Biomarkers in Cardiology 
recommended the routine use of hsTnT as a diagnostic biomarker for AMI in 2012,27 possibly leading 
to additional identification of cases since. Data from the other European countries and the United 
States also have reported an increase in the incidence of NSTEMI.28–32  Contrary to the trends in CAD, 
there was a 15% reduction in the standardised incidence of PAD during the study period. The fall in 
the incidence rates of PAD could be due to policy measures incorporating primary prevention of 
ASCVD. Moreover, a significant proportion (30 - 50%) of PAD patients have CAD prior to their 
diagnosis33, which could have led to an increased uptake of CV medications. 
There was a notable shift in the co-morbidity burden over the last decade, especially in patients with 
incident PAD. Patients diagnosed with PAD in the more recent years (2014-15) were sicker, with a 
significantly higher proportion of patients with obesity, DM, HLD, CKD, COPD and malignancy, 
compared to those diagnosed in 2006-07. It is plausible that the rising trends in the CV and non CV co-
morbidities from 2006-07 to 2010-11 may be partly related to the differences in coding practices, due 
to the introduction of new indicators to Quality and Outcomes framework in 2008, a system for the 
performance management and payment of general practitioners in the National Health service.34,35 
However, it is unlikely that the changes observed in the later part of the study period (2010-11 to 
2014-15) are related to a change in coding practice.  
Our findings suggest, in spite of consistent evidence from multiple RCTs that statins reduce recurrent 
CV events in patients with established ASCVD, statins remain underutilized in clinical practice in the 
UK.  A substantial segment of incident CAD (~ 1 out of every 3 CAD patients) and incident PAD (~ 1 out 
of every 2 PAD patients) patients were not receiving long term statin therapy. These findings are in 
line with the results of other large studies such as the PURE study and the SHARE study, where 30-
40% of patients with established ASCVD in the developed countries were not prescribed with statin.25, 
39, 40 We observed the phenomenon of “risk treatment paradox” 39 in our study population i.e., ASCVD 
patients at higher risk (elderly, female, CHF, COPD and depression) for CV outcomes were less likely 
to have been prescribed persistent statin therapy by their physicians. Meta-analysis of individual data 
of 174,000 patients by the Cholesterol Treatment Trialists’ (CTT) collaboration, showed significant 
reductions in recurrent CV events with statin among elderly patients with pre-existing vascular 
disease.40,41 However, we observed an inverse relationship between treatment propensity and age 
with regard to statins. Among all the variables, female sex was the most significant predictor to have 
negatively influenced physician prescribing pattern with statins, after accounting for important 
confounders. Despite compelling evidence of the benefits of statin in women, 42 the reasons for the 
barriers in clinical practice remains unclear. Female gender has been shown to be a risk factor for 
statin induced myalgias, which could have led to an early discontinuation. 43It has also been shown 
that intense media publicity of exaggerated side effects of statins may have had a negative impact on 
continuation of statins, with more profound effects on women.44,45 Our findings shine a spotlight on 
the necessity to highlight sex specific disparities in the utilisation of statins in clinical practice to 
patients and physicians, and the imperative to implement additional sex specific strategies to improve 
CV outcomes for women.  
The trends in outcomes from 2006 to 2015 suggest that the reduction in the annual CV event rates 
and CV mortality in patients with incident CAD outpaced their PAD counterparts (even after excluding 
patients with concomitant CAD) (Figure 4 and Supplementary Figures S10-S13). The significant decline 
in recurrent CV events, recurrent CV hospitalisation and CV mortality among patients with incident 
CAD in the latter part of our study could be a consequence of improvements in treatment, particularly 
the health care policy measures related to early revascularisation in AMI, and secondary prevention 
with the introduction of newer pharmacological agents (e.g., newer antiplatelet therapy).46–48 
However, this could also be related to an increase in the frequency of detecting smaller infarcts with 
less severity after the widespread utilisation of hsTnT. Conversely, in patients with incident PAD, there 
was no significant reduction in CV mortality over time. There are several potential explanations for 
this. Our study shows that the prevalence of smoking, one of the most important risk factors for PAD, 
has not changed over time. In addition to increasing the risk of incident PAD, cigarette smoking has 
shown to negatively impact functional capacity and increase CV mortality among patients with 
prevalent PAD. 49In the UK, a primary care service network was established for evaluation of 
symptomatic PAD in primary care in 2009. However, the onset of symptoms in PAD indicates advanced 
systemic atherosclerosis and the effect of disease modifying CV medications might be less than what 
is observed in patients with CAD alone. A significant proportion of patients with PAD have established 
atherosclerosis in other vascular beds which could have an additive or multiplicative effect on CV 
mortality. However, sensitivity analyses of incident PAD patients excluding those with concomitant 
CAD demonstrated results comparable to the overall incident PAD patients (Supplementary Figure 
S10).  
Limitations 
Our study has several strengths but some limitations. While we hypothesize that the introduction of 
hsTnT could have led to an overestimation in the incidence of CAD after 2012 (due to an increase in 
NSTEMI cases), we were not able to perform a stratified analyses by AMI type, as it has been shown 
that ICD10 subcategory codes, are insufficient to distinguish AMI type. 50CPRD captures medications 
that are prescribed to patients. The fact that the patient received a prescription for a medication does 
not ensure that the patient actually filled or even took the medication. In addition, over-the-counter 
medication use or medications administered during hospitalisations were not captured. Our analyses 
was also restricted to the use of statin and not the dosage of statins (high potency statins) which is 
clinically relevant with the recent changes in guidelines. 51 Only 60% of the CPRD patients eligible for 
HES and ONS linkage were included for the vascular events and mortality analyses. Another limitation 
of research using electronic health records includes the potential for misclassification of diseases and 
of the outcomes. Wherever possible, definitions and algorithms that have been validated in these data 
sources were preferentially used to identify both the diseases of interest as well as complications. 52–
54  
Conclusion  
In conclusion, the standardised incidence of CAD appears stable but mortality rates are falling, 
whereas the standardised incidence of PAD is falling but mortality rates are not. The stable incidence 
of CAD, despite primary prevention measures, remains an important concern for healthcare policy 
planning for an aging population. In the general population, statin use for secondary prevention 
remains suboptimal and the uptake has not increased in the past decade, necessitating measures to 
address this gap. Our findings also highlight the importance of identification of PAD early in the course 
of the disease where disease modifying interventions (e.g., counselling and therapies targeting 
smoking cessation) may improve CV outcomes.   
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Table 1: Baseline characteristics of patients with incident CAD (2006 -2015) 
 
*Data available on socioeconomic status was available only for patients eligible for HES linkage n=114,807; 
BMI: Underweight: <18·5 kg/m2; Normal: 18·5-24·9 kg/m2, Overweight: 25-29·9 kg/m2, Obesity: 30-39·9 kg/m2, 
Morbid obesity: > 40 kg/m2; ACEI/ARB; Angiotensin Converting Enzyme Inhibitor/ Angiotensin Receptor 
Blocker  
 All patients Sex   Time period   










Age        
Age (years) (SD) 69·1 (13·7) 66·6 (13·2) 72·6 (13·7)  69·2 (13·5) 69·2 (13·7) 68·8 (13·8) 
Age > 75 years 60,977 (38·0%) 27,232 (29·7%) 33,744 (49·1%)  11,016 (38·5%) 13,361 (37·9%) 9,407 (37·3%) 
Sex        
Women 68,708 (42·8%) N/A N/A  12,366 (43·2%) 15,191 (43·1%) 10,530 (41·7%) 
Men 91,668 (57·2%) N/A N/A  16,225 (56·8%) 20,096 (56·9%) 14,739 (58·3%) 
Ethnicity        
White 43,298 (52·1%) 24,668 (56·9%) 18,629 (43·0%)  6,457 (14·1%) 10,141 (23·4%) 7,281 (16·8%) 
Missing data 48·80% 48·80% 48·80%  59·70% 47·20% 43·70% 
Socio economic quintile*  
Quintile 1 23,010 (20·0%) 13,389 (20·8%) 9,621 (19·0%)  4,319 (19·5%) 5,197 (20·4%) 3,475 (20·9%) 
Quintile 2 26,128 (22·8%) 14,808 (23·1%) 11,320 (22·4%)  5,174 (23·4%) 5,842 (22·9%) 3,749 (22·6%) 
Quintile 3 24,173 (21·1%) 13,574 (21·1%) 10,599 (21·0%)  4,586 (20·7%) 5,304 (20·8%) 3,483 (30·0%) 
Quintile 4 22,569 (19·7%) 12,294 (19·1%) 10,275 (20·3%)  4,293 (19·4%) 4,895 (19·2%) 3,274 (19·7%) 
Quintile 5 (most deprived) 18,927 (16·5%) 10,189 (15·9%) 8,738 (17·3%)  3,780 (17·1%) 4,261 (16·7%) 2,638 (15·9%) 
Body Mass Index        
Mean kg/m2 (SD) 27·2 (5·9) 27·9 (5·3) 27·7 (6·5)  27·4 (5·7) 27·9 (5·9) 28·1 (6·0) 
Underweight 2,710 (2·9%) 851 (1·7%) 1,859 (4·5%)  542 (3·0%) 615 (3·0%) 340 (2·6%) 
Normal 27,096 (29·2%) 13,877 (26·9%) 13,218 (32·2%)  5,605 (31·2%) 5,890 (28·7%) 3,713 (28·5%) 
Overweight 34,722 (37·4%) 21,615 (41·8%) 13,107 (31·9%)  6,793 (37·9%) 7,736 (37·6%) 4,748 (36·4%) 
Obesity 25,054 (27·0%) 14,003 (27·1%) 11,050 (26·9%)  4,512 (25·1%) 5,562 (27·1%) 3,753 (28·8%) 
Morbid obesity 3,200 (3·5%) 1,329 (2·6%) 1,871 (4·6%)  495 (2·8%) 749 (3·6%) 494 (3·8%) 
Missing data 42·00% 43·00% 40·00%  37·00% 42·00% 48·00% 
Smoking        
Current smoker 38,335 (23·9%) 21,323 (23·3%) 17,009 (24·8%)  6,702 (23·4%) 8,537 (24·2%) 6,051 (24·0%) 
Ex-smoker    43,431 (26·5%) 27,524 (30·0%) 15,817 (23·0%)  8,565 (30·0%) 9,558 (27·1%) 5,955 (23·6%) 
No 74,136 (46·2%) 40,512 (44·2%) 33,624 (48·9%)  12,742 (44·6%) 16,170 (45·8%) 12,400 (49·1%) 
Missing data 4,564 (2·9%) 2,309 (2·5%) 2,255 (3·3%)  582 (2·0%) 1,023 (2·9%) 863 (3·4%) 
Co-morbidities        
Diabetes Mellitus 30,611 (19·0%) 17,668 (19·3%) 12,941 (18·8%)  4,552 (15·9%) 6,658 (18·8%) 5,684 (22·5%) 
Hypertension 100,037 (62·4%) 52,187 (56·9%) 47,847 (69·6%)  17,567 (61·4%) 21,812 (61·9%) 15,779 (62·4%) 
Dyslipidaemia 33,358 (20·8%) 18,379 (20·0%) 14,979 (21·8%)  5,278 (18·5%) 7,451 (21·4%) 5,849 (23·1%) 
Atrial fibrillation 18,398 (11·5%) 9,949 (10·9%) 8,449 (12·3%)  2,984 (10·4%) 4,023 (11·4%) 3,011 (11·9%) 
Chronic Heart Failure 11,818 (7·4%) 6,218 (6·8%) 5,600 (8·2%)  2,297 (8·0%) 2,484 (7·0%) 1,851(7·3%) 
Stroke 13,279 (8·3%) 6,967 (7·6%) 6,312 (9·2%)  2,033 (7·1%) 3,067 (8·7%) 2,201 (8·7%) 
Peripheral arterial disease 10,810 (6·7%) 6,747 (7·4%) 4,063 (5·9%)  1,890 (6·6%) 2,499 (7·1%) 1,561 (6·2%) 
Chronic Kidney Disease 26,001 (16·2%) 11,616 (12·7%) 14,385 (20·9%)  2,852 (10·0%) 6,351 (18·0%) 4,311 (17·1%) 
Chronic Obstructive 
Pulmonary Disease 
14,848 (9·3%) 8,352 (9·1%) 6,494 (9·5%)  2,431 (8·5%) 3,340 (9·5%) 2,479 (9·8%) 
Depression 13,034 (8·1%) 5,966 (6·5%) 7,068 (10·3%)  2,485 (8·7%) 2,822 (8·0%) 1,952 (7·7%) 
Cancer 13,715 (8·6%) 7,402 (8·1%) 6,312 (9·2%)  2,109 (7·4%) 3,164 (9·0%) 2,437 (9·6%) 
High bleeding risk 12,558 (12·2%) 7,169(7·8%) 5,389 (7·8%)  2,044 (7·1%) 2,712 (7·7%) 2,173 (8·6%) 
Baseline Medications        
Statins 62,571 (39·0%) 35,608 (38·8%) 26,963 (39·2%)  9,838 (34·4%) 14,265 (40·4%) 10,526 (41·7%) 
At least one antiplatelet therapy 52,439 (32·7%) 28,108 (30·7%) 24,331 (35·4%)  9,871 (34·5%) 11,904 (33·7%) 7,103 (28·1%) 
ACEI/ARB 60,419 (37·8%) 32,900 (35·9%) 27,518 (40·1%)  9,627 (33·7%) 13,572 (38·5%) 9,822 (38·7%) 
Diuretics 49,773 (31·0%) 22,207 (24·2%) 27,566 (40·1%)  10,016 (35·0%) 10,841 (30·7%) 6,678 (26·4%) 
Beta-blockers 34,567 (21·5%) 17,725 (19·3%) 16,841 (24·5%)  6,463 (22·6%) 7,366 (20·9%) 3,756 (21·9%) 
Calcium channel blockers 17,911 (11·1%) 8,887 (9·7%) 9,024 (13·1%)  3,632 (12·7%) 3,916 (11·7%) 2,294 (9·1%) 
Vasodilators 14,894 (9·3%) 7,708 (8·4%) 7,186 (10·5%)  3,008 (10·5%) 3,138 (8·9%) 2,121 (8·4%) 
Table 2 Baseline characteristics of patients with incident PAD (2006 -2015) 
  All patients  Sex    Time period      











Age              
Age, mean in years (SD) 70·4 (13·8) 69·5 (12·5) 71·8 (15·5)  71·0 (13·5) 70·0 (14·0) 70·3 (13·8) 
Elderly (age > 75) 30,126 (42·6%) 15,930 (37·3%) 14,196 (50·5%)  8,493 (55·3%) 6,035 (40·7%) 4,584 (41·2%) 
Sex              
Women 28,090 (39·7%) N/A N/A  6,190 (40·3%) 5,926 (40·0%) 4,228 (38·0%) 
Men  42,663 (60·3%) N/A N/A  9,169 (59·7%) 8,886 (60·0%) 6,904 (62·0%) 
Ethnicity              
White 19,848 (57·0%) 12,105 (57·1%) 7,743 (56·4%)  3,269 (57·3%) 4,380 (57·0%) 3,527 (56·8%) 
Missing data 51% 51% 51%  61% 48% 45% 
Socioeconomic quintile               
Quintile 1 8,441 (18·5%) 5,059 (18·6%) 3,382 (18·4%)  1,827 (18·0%) 1,850 (19·4%) 1,219 (18·1%) 
Quintile 2 10,195 (22·4%) 6,142 (22·6%) 4,053 (22·1%)  2,248 (22·1%) 2,117 (22·2%) 1,512 (22·5%) 
Quintile 3 9,591 (21·0%) 5,716 (21·0%) 3,875 (21·1%)  2,085 (20·5%) 2,054 (21·5%) 1,419 (21·1%) 
Quintile 4 9,537 (20·9%) 5,686 (20·9%) 3,851 (21·0%)  2,141 (21·1%) 1,901 (19·9%) 1,529 (22·7%) 
Quintile 5 (most deprived) 7,815 (17·2%) 4,611 (16·9%) 3,201 (17·5%)  1,867 (18·4%) 1,618 (17·0%) 1,057 (15·7%) 
Body Mass Index              
Mean, kg/m2 (SD) 26·9 (5·7) 27·1 (5·2) 26·5 (6·3)  26·6 (5·5) 26·9 (5·7) 27·4 (6·0) 
Underweight  1,737 (4·1%) 643 (2·5%) 1,094 (6·4%)  376 (3·8%) 345 (3·9%) 233 (4·0%) 
Normal 14,859 (34·9%) 8,382 (32·7%) 6,477 (38·1%)  3,589 (36·6%) 3,073 (34·6%) 1,863 (32·0%) 
Overweight 15,321 (36·0%) 10,147 (39·6%) 5,174 (30·4%)  3,530 (36·0%) 3,190 (35·9%) 2,090 (35·9%) 
Obesity 9,653 (22·7%) 5,941 (23·2%) 3,712 (21·8%)  2,124 (21·7%) 2,066 (23·3%) 1,420 (24·4%) 
Morbid obesity 1,737 (4·1%) 489 (1·9%) 561 (3·3%)  191 (2·0%) 204 (2·3%) 209 (3·6%) 
Missing data 40% 40% 40%  36% 40% 48% 
Smoking              
Current smoker 21,835 (29·9%) 12,433 (29·1%) 8,751 (31·2%)  4,269 (27·8%) 4,708 (31·8%) 3,338 (30·0%) 
Ex-smoker 19,632 (27·8%) 13,367 (31·3%) 6,265 (22·3%)  4,465 (29·1%) 4,128 (27·9%) 2,770 (24·9%) 
Never smoked 129,437 
(41·6%) 
16,611 (38·9%) 12,826 (45·7%) 
 
6,457 (42·0%) 5,884 (39·7%) 4,959 (44·6%) 
Missing data 499 (0·7%) 251 (0·6%) 248 (0·9%)  168 (1·1%) 92 (0·6%) 65 (0·6%) 
Co-morbidities              
Diabetes Mellitus 17,561 (24·8%) 11,309 (26·5%) 6,251 (22·3%)  3,389 (22·1%) 3,455 (23·3%) 3,368 (30·3%) 
Hypertension 46,129 (65·2%) 27,321 (64·0%) 18,807 (67·0%)  10,164 (66·2%) 9,368 (63·2%) 7,312 (65·7%) 
Dyslipidaemia 16,642 (23·5%) 10,151 (23·8%) 6,491 (23·1%)  3,211 (20·9%) 3,455 (23·3%) 2,966 (26·6%) 
Atrial fibrillation 8,614 (12·2%) 5,163 (12·1%) 3,451 (12·3%)  1,718 (11·2%) 1,845 (12·5%) 1405 (12·6%) 
Chronic Heart Failure 6,047 (8·5%) 3,799 (8·9%) 2,248 (8·0%)  1,480 (9·6%) 1,196 (8·1%) 939 (8·4%) 
Stroke 6,353 (9·0%) 3,857 (9·0%) 2,496 (8·9%)  1,466 (9·5%) 1,318 (8·9%) 999 (9·0%) 
Coronary artery disease 17,971 (25·1%) 12,521 (29·3%) 5,450 (19·4%)  4,378 (28·5%) 3,590 (24·2%) 2,534 (22·8%) 
Chronic Kidney Disease 14,026 (19·8%) 7,467 (17·5%) 6,559 (23·3%)  2,147 (14·0%) 3,127 (21·1%) 2,293 (20·6%) 
Chronic Obstructive 
Pulmonary Disease 
8,582 (12·1%) 5,453 (12·8%) 3,128 (11·1%) 
 
1,680 (10·9%) 1,757 (12·4%) 1,528 (13·7%) 
Depression 5,625 (8·0%) 2,694 (6·3%) 2,930 (10·4%)  1,288 (8·3%) 1,240 (8·7%) 829 (7·4%) 
Malignancy 6,791 (9·6%) 4,153 (9·7%) 2,637 (9·4%)  1,299 (8·5%) 1,480 (10·0%) 1,208 (10·9%) 
High bleeding risk 5,452 (7·7%) 3,318 (7·8%) 2,134 (7·6%)  1,186 (7·7%) 1,115 (7·5%) 903 (8·1%) 
Baseline Medications              
Statins 31,844 (45·0%) 20,842 (48·9%) 11,002 (39·2%)  6,399 (41·2%) 6,668 (45·0%) 5,337 (47·9%) 
At least one antiplatelet 
therapy 
27,059 (38·2%) 17,296 (40·5%) 9,763 (34·8%) 
 
6,396 (41·7%) 5,593 (37·8%) 3,802 (34·2%) 
ACEI/ARB 30,241 (42·7%) 18,664 (43·7%) 11,337 (40·4%)  6,313 (41·1%) 6,269 (42·3%) 4,817 (43·3%) 
Diuretics 23,610 (33·4%) 12,413 (29·1%) 11,197 (39·9%)  6,033 (39·3%) 4,663 (31·5%) 3,204 (28·9%) 
Beta-blockers 18,421 (26·0%) 11,460 (26·7%) 6,961 (24·8%)  4,156 (27·1%) 3,734 (25·2%) 2,909 (26·1%) 
Calcium channel blockers 8,629 (12·2%) 5,112 (12·0%) 3,517 (12·5%)  2,303 (15·0%) 1,698 (11·5%) 1,050 (9·4%) 
Vasodilators 8,721 (12·3%) 5,410 (12·7%) 3,311 (11·8%)  2,320 (15·1%) 1,672 (11·3%) 1,159 (10·4%) 
*Data available on socioeconomic status was available only for patients eligible for HES linkage n=114,807; 
BMI: Underweight: <18·5 kg/m2; Normal: 18·5-24·9 kg/m2, Overweight: 25-29·9 kg/m2, Obesity: 30-39·9 kg/m2, 
Morbid obesity: > 40 kg/m2; ACEI/ARB; Angiotensin Converting Enzyme Inhibitor/ Angiotensin Receptor 
Blocker  
Table3: Baseline characteristics of CAD and PAD patients with and without statins 
  Statin prescriptions (CAD)  
 
Statin prescriptions (PAD) 
  Yes (n=79,641) No (n=41,370) 
 
Yes (n=27,150) No (n=22,276) 
Age (years), mean (SD) 67·3(11·6) 69·2(13·5) 
 
70·7 (10·1) 70·4 (12·5) 
Age 40-49 years 5,590 (7·0%) 3,789 (9·2%) 
 
664 (2·4%) 1,228 (5·5%) 
Age 50-59 years 15,170 (19·0%) 7,031 (17·0%) 
 
3170 (11·7%) 3,496 (15·7%) 
Age 60-69 years 23,800 (29·9%) 9,474 (22·9%) 
 
7,989 (29·4%) 5,480 (24·6%) 
Age 70-79 years 22,254 (27·9%) 10,295 (24·9%) 
 
9,716 (35·8%) 5,995 (26·9%) 
Age > 80 years 12,820 (16·1%) 10,873 (26·3%) 
 
5,611 (20·7%) 6,077 (27·3%) 
Sex     
 
    
Women 29,687 (37·3%) 20,713 (50·1%) 
 
9,143 (33·7%) 9,086 (40·8%) 
Men  49,960 (62·7%) 20,744 (50·1%) 
 
18,007 (66·3%) 13,189 (59·2%) 
Socioeconomic quintile      
 
    
Quintile 1 10,873 (21·4%) 6,009 (19·5%) 
 
3,001 (18·4%) 2,490 (18·2%) 
Quintile 2 11,776 (23·2%) 6,874 (22·3%) 
 
3,665 (22·4%) 3,001 (22·0%) 
Quintile 3 10,459 (20·6%) 6,711 (21·8%) 
 
3,315 (20·4%) 2,926 (21·4%) 
Quintile 4 9,670 (19·2%) 6,132 (19·9%) 
 
3,523 (21·6%) 2,913 (21·3%) 
Quintile 5 8,053 (15·8%) 5,111 (16·6%) 
 
2,796 (17·2%) 2,322 (17·0%) 
Smoking     
 
    
Current smoker 19,946 (25·7%) 9,993 (24·7%) 
 
8,265 (30·4%) 7,713 (34·6%) 
Co-morbidities     
 
    
Diabetes Mellitus 16,276 (20·4%) 6,076 (14·7%) 
 
8,578 (31·6%) 4,108 (18·4%) 
Hypertension 48,789 (61·3%) 24,748 (59·8%) 
 
20,553 (75·7%) 12,768 (57·3%) 
Prior acute coronary syndrome 29,660 (37·2%) 6,104 (14·8%) 
 
4,906 (18·1%) 1,613 (7·2%) 
Stroke 6,179 (7·8%) 2,997 (7·2%) 
 
2,824 (10·4%) 1,305 (5·9%) 
Peripheral arterial disease/Coronary artery disease 5,418 (6·8%) 2,327 (5·6%) 
 
9,641 (35·5%) 3,598 (16·1%) 
Chronic Kidney Disease 10,760 (13·5%) 6,428 (15·5%) 
 
5,603 (20·6%) 3,617 (16·2%) 
Heart Failure 4,143 (5·2%) 3,418 (8·3%) 
 
2,289 (8·2%) 1,454 (6·5%) 
Dementia 2,296 (2·9%) 1,610 (3·9%) 
 
1,035 (3·8%) 806 (3·6%) 
COPD 6,221 (7·8%) 4,132 (10·0%) 
 
3,318 (12·2%) 2,882 (12·9%) 
Chronic Liver Disease 880 (1·1%) 647 (1·6%) 
 
348 (1·2%) 383 (1·7%) 
Depression 6,071 (7·6%) 3,754 (9·1%) 
 
2,088 (7·7%) 1,782 (8·0%) 
Malignancy 5,610 (7·0%) 3,635 (8·8%) 
 
2,326 (8·6%) 2,106 (9·5%) 
Management      
 
    
Mean number of medications during follow up, mean 
(SD) 
5·5 (4·0) 5·4 (4·1) 
 
5·9 (4·4) 5·6 (4·3) 
      
      
COPD: Chronic Obstructive Pulmonary Disease 
 
Table 4 Complications of patients with incident CAD and PAD 
 
Annual crude incidence 
rate per 100-person 
years, 95% CI 
Standardized annual incidence rate per 100-person years, 95% CI 
  
Age and sex standardized   Male (age standardized) Female (age 
standardized)  
Incident CAD          
MI 3·1 (3·0 - 3·2) 2·4 (2·3 - 2·5) 2·8 (2·6 - 2·9) 1·7 (1·6 - 1·8) 
Ischemic Stroke 2·1 (2·0 - 2·2) 1·4 (1·3 - 1·4) 1·2 (1·1 - 1·3) 1·6 (1·5 - 1·7) 
Hospitalization for bleeding 2·5 (2·4 - 2·6) 1·7 (1·6 - 1·8) 1·9 (1·8 - 2·0) 1·5 (1·4 - 1·6) 
CV hospitalization 11·8 (11·6 - 12·0) 9·7 (9·5 - 9·9) 10·1 (9·8 - 10·4) 9·1 (8·8 - 9·3) 
Premature CV death  2·2 (2·1 - 2·4) 2·0 (1·9 - 2·1) 2·2 (2·1 - 2·3) 1·7 (1·5 - 1·8) 
Premature death from any cause 6·1 (5·9 - 6·3) 4·5 (4·4 - 4·6) 4·5 (4·4 - 4·6) 4·4 (4·2 - 4·7) 
CV death 7·8 (7·6 - 8·0) 3·7 (3·6 - 3·8) 3·8 (3·7 - 3·9) 3·5 (3·4 - 3·6) 
Death from any cause 17·1 (16·8 - 17·4) 8·2 (8·1 - 8·4) 8·3 (8·1 - 8·4) 8·2 (8·0 - 8·4) 
Incident PAD          
MI 2·9 (2·7 - 3·1) 1·9 (1·8 - 2·0) 2·3 (2·1 - 2·4) 1·4 (1·3 - 1·5) 
Ischemic Stroke 2·6 (2·4 - 2·7) 1·6 (1·5 - 1·7) 1·7 (1·5 - 1·8) 1·4 (1·3 - 1·6) 
Hospitalization for bleeding 2·1 (2·0 - 2·3) 1·4 (1·3 - 1·5) 1·6 (1·4 - 1·7) 1·2 (1·1 - 1·2) 
CV hospitalization 10·3 (10·0 - 10·6) 6·6 (6·4 - 6·7) 7·8 (7·5 - 8·1) 4·9 (4·7 - 5·2) 
Premature CV death  2·5 (2·3 - 2·8) 2·1 (1·9 - 2·3) 2·3 (2·1 - 2·5) 1·9 (1·6 - 2·1) 
Premature death from any cause 8·3 (8·0 - 8·7) 6·2 (5·8 - 6·4) 7·3 (6·9 - 7·8) 7·2 (6·5 - 7·9) 
CV death 7·6 (7·3 - 7·8) 3·5 (3·3 -3·6) 3·7 (3·5 - 3·9) 3·5 (3·3 - 3·6) 
Death from any cause 18·5 (18·1 - 18·9) 9·2 (9·0 - 9·5) 9·1 (8·7 - 9·4) 9·6 (9·3 - 9·9) 
MI: Myocardial infarction, CV hospitalization: cardiovascular hospitalization (planned and unplanned), 
Premature CV death: Death <75 years of age due to cardiovascular cause, CV death: Death due to 
cardiovascular cause 
Figure 1 A) Age and sex standardized incidence rates (per 100,000 person years) of CAD in the UK in 
2006 vs 2015; 1 B) Age and sex standardized incidence rates (per 100,000 person years) of PAD in 
the UK in 2006 vs 2015 
** IRR: incidence rate ratio adjusted for age and sex; CAD: coronary artery disease; PAD: peripheral artery disease 
** Figure 1A shows stable standardized incidence rates of CAD between 2006 and 2015; Figure 1B shows a 
decline in the standardized incidence of PAD between 2006 and 2015 
 
Figure 2 A) Number of cases stratified by age group (per total person years of follow in each age 
category) of CAD in the UK in 2006 vs 2015; 2 B) Number of cases stratified by age group (per total 
person years of follow in each age category) of PAD in the UK in 2006 vs 2015 
** IRR: incidence rate ratio adjusted for age and sex; CAD: coronary artery disease; PAD: peripheral artery disease 
** Figure 2A shows no significant change in the crude incidence of CAD between 2006 and 2015; Figure 2B shows 
a decline in the crude incidence of PAD between 2006 and 2015 
 
Figure 3; Predictors of statin use for secondary prevention among patients with incident CAD and 
incident PAD 
**Statin analyses was performed separately for incident CAD and incident PAD patients. The model was adjusted 
for age, sex, and relevant co-morbidities including, diabetes mellitus,, hypertension, chronic kidney disease, 
chronic obstructive pulmonary disease, depression, dementia, history of malignancy, chronic liver disease, and 
prior history of stroke; additionally, prior history of PAD was included in the model for incident CAD patients and 
prior history of CAD was included the model for incident PAD patients 
Figure 4; Trends in the annual age and sex adjusted event rates of major vascular events, bleeding, 
hospitalization and mortality among patients with incident CAD and incident PAD in 2006 vs 2015 
** MI: Myocardial infarction, CV hospitalization: cardiovascular hospitalization (planned and unplanned), 
Premature CV death: Death <75 years of age due to cardiovascular cause, CV death: Death due to cardiovascular 
cause 
 
